



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

18 Jan 2017 (#2)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- New Appendix policy for NIH/AHRQ/NIOSH Applications submitted for Due Dates On or After January 25, 2017 ([NOT-OD-17-035](#))
- Request for Information (RFI) for Investigating the Role of Microbiome in Heart, Lung, and Blood Diseases and Sleep Disorders in HIV-infected Individuals ([NOT-HL-16-482](#))
- Fogarty Fellow Dr. Laura Lewandowski studies [lupus in South African children](#)

1. Strengthening the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum through Behavioral, Social, and Implementation Science

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: ([PA-17-103](#))
([PA-17-104](#))

Type: R21
R01

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) This Funding Opportunity Announcement (FOA) encourages behavioral, social, and implementation science research designed to (a) identify gaps in the HIV pre-exposure prophylaxis (PrEP) care continuum and associated determinants; (b) develop and test interventions to strengthen PrEP delivery, use, and outcomes; and (c) reduce racial/ethnic and age-related disparities in PrEP uptake and use. High risk/high payoff projects that lack preliminary data are appropriate for the R21 mechanism, while applicants with preliminary data who propose longitudinal analyses and/or large scale projects may consider the R01 mechanism.

Budget: R21 -The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Targeted basic behavioral and social science and intervention development for HIV prevention and care

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: ([PA-17-105](#))
([PA-17-106](#))

Type: R21
R01

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) This Funding Opportunity Announcement (FOA) encourages innovative, targeted basic behavioral and social science and intervention development research to reduce incident HIV infections and improve the health of those living with HIV. This FOA encourages research designed to (a) conduct basic behavioral and social science research that is needed to advance the development of HIV prevention and care interventions, (b) translate and operationalize the findings from these basic studies to develop interventions and assess their acceptability and feasibility and (c) conduct tests of the efficacy of HIV prevention and care interventions. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data and/or include longitudinal analysis may wish to apply using the R01 mechanism.

Budget: R21 -The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older adults.

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-109\)](#)
[\(PA-17-110\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data and/or include longitudinal analysis may wish to apply using the R01 mechanism.

Budget: R21 -The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Fc Receptor (FcR) and Antibody Effector Function in HIV Vaccine Discovery

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-113\)](#)

Type: R01

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate and support investigator-driven collaborative research to: 1) probe how vaccine-elicited antibodies protect against viral acquisition via Fc receptor (FCR)-mediated mechanisms; and 2) determine the functional profiles of Fc receptor engagement in the context of immune responses elicited by protective vaccines, to inform advancement of similarly promising HIV vaccine candidates.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. NK Cells to Induce Immunological Memory to Prevent HIV Infection

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-114\)](#)

Type: R01

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary, hypothesis-driven research on Natural Killer (NK) cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Chronic Condition Self-Management in Children and Adolescents

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-116\)](#)
[\(PA-17-115\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to improve self-management and quality of life in children and adolescents with chronic conditions. Managing a chronic condition is an unremitting responsibility for children and their families. Children with a chronic condition and their families have a long-term responsibility for self-management. This FOA encourages research that takes into consideration various factors that influence self-management such as individual differences, biological and psychological factors, family/caregivers and sociocultural context, family-community dynamics, healthcare system factors, technological advances, and the role of the environment.

Budget: R21 -The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Reducing Health Disparities Among Minority and Underserved Children

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-117\)](#)
[\(PA-17-118\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non-traditional settings

Budget: **R21** -The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **R01** - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

8. Basic Mechanisms of Brain Development Mediating Substance Use and Dependence

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-119\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) encourages applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behavior and in substance use and dependence. All stages of brain development are of interest, but a new emphasis of the current reissue of this initiative is to support basic neuroscience research on fundamental mechanisms of brain development during prepuberty and the adolescent period in relation to the problems of substance abuse and co-morbidity with psychiatric disorders. Topics of interest pertaining to brain development of this initiative include, but are not limited to, the euphoric properties of abused substances, actions of psychotherapeutic agents, and their consequences on memory, cognitive and emotional processes. A major goal of this initiative is to understand how exposure to substances of abuse and environmental insults affects the cellular and molecular mechanisms underlying nervous system development and neural circuit functions implicated in substance use and addiction.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. National Institute of Neurological Disorders and Stroke Exploratory Clinical Trials

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-122\)](#)

Type: R01

Application Due Date: March 21, 2017 and then [Standard dates](#) and May 7, 2017 then [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<http://www.ninds.nih.gov/>)

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

